| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. (ELVN) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 13 sells. ELVN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 7.39M | $441.12M | - | |
| CEO | 890.4K | $53.16M | - | |
| CEO | 875.0K | $52.24M | - | |
| Other | 740.2K | $44.19M | - | |
| COO | 215.3K | $12.85M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 29, 2025 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE | 3,250 | $20.40 | $66,291.23 | -12.4% | -21.5% | - | |
| Sep 26, 2025 | Lyssikatos Joseph P49 | Chief Scientific Officer | Sell | 4,000 | $20.25 | $81,005.20 | -0.4% | -18.5% | - | |
| Sep 26, 2025 | Kintz Samuel50 | President And CEO | Sell | 3,700 | $20.06 | $74,227.55 | -0.4% | -18.5% | - | |
| Sep 23, 2025 | Lyssikatos Joseph P49 | Chief Scientific Officer | Sell | 1,500 | $20.03 | $30,045.00 | -0.2% | -6.6% | - | |
| Sep 23, 2025 | Kintz Samuel50 | President And CEO | Sell | 2,800 | $20.03 | $56,084.00 | -0.3% | -6.6% | - | |
| Sep 19, 2025 | Lyssikatos Joseph P49 | Chief Scientific Officer | Sell | 7,000 | $19.39 | $135,697.35 | -0.4% | -12.0% | - | |
| Sep 19, 2025 | Kintz Samuel50 | President And CEO | Sell | 6,000 | $19.29 | $115,723.00 | -0.3% | -12.0% | - | |
| Sep 8, 2025 | Patel Anish53 | Chief Operating Officer | Sell | 6,667 | $20.24 | $134,957.41 | -2.3% | +2.5% | - | |
| Aug 27, 2025 | Hohl Benjamin59 | Chief Financial Officer | Sale+OE | 3,250 | $20.63 | $67,038.73 | -12.4% | +4.9% | - | |
| Aug 21, 2025 | Lyssikatos Joseph P49 | Chief Scientific Officer | Sell | 12,500 | $19.86 | $248,216.50 | -0.7% | +11.4% | - |